For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased risk for psychiatric adverse events or worsening ...

Despite her active and healthy lifestyle, Sasha Barden felt stuck in her weight loss journey. She decided to try GLP-1 ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

There were associations for GLP-1 RA treatment vs placebo with improvements in restrained eating and emotional eating behavior and in mental health-related QOL. HealthDay News — For patients ...

GLP-1 receptor agonists are associated with improvements in restrained eating, emotional eating behavior, QOL. (HealthDay News) — For patients with overweight/obesity and/or diabetes ...

VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

During recovery, her depression, overeating and inactivity ... a $1,600-a-month medication in a class called glucagon-like peptide-1 agonist (GLP-1). After a diabetes diagnosis, Carter-Williams ...

GLP-1 RAs are highly effective in treating obesity ... have a higher baseline risk for psychiatric symptoms, including depression and suicidal ideation. “Previously observed signals of ...

Another unexpected impact of GLP-1 RAs is their potential influence on mental health. While many patients report improved mood and mental clarity, some experience negative side effects such as anxiety ...